3rd Annual Miami Lung Cancer Conference®
3rd Annual Miami Lung Cancer Conference®March 19, 2016
Eden Roc Miami
4525 Collins Avenue
Miami Beach, FL 33140
The Miami Lung Cancer Conference®
returns for its 3rd
year, and will bring updates on the latest advances in current and future approaches for lung cancer treatment. This 1-day meeting will address immunotherapies and targeted agents both approved and in development, treatment for special populations, and a look forward from the experts.
The Conference is led by our co-chairs, Thomas J. Lynch, Jr, MD and Heather A. Wakelee, MD, leading experts in lung cancer. Participants will learn from engaging presentations delivered by thought leaders, reviewing and discussing realistic and complex scenarios, sharing clinical experiences, evaluating well-established and emerging unmet therapeutic opportunities, solving clinical problems, and clarifying best practices. This year’s offering will again feature the dynamic and interactive Medical Crossfire® discussion panels, allowing for exploration of some of the most challenging topics for which there may exist potential approaches to care. As a result of this exploration, participants will leave the Miami Lung Cancer Conference® with a higher level of comprehension than they would otherwise have achieved.
This educational activity is directed toward oncologists involved in the treatment and management of patients with lung cancers. Nurse practitioners (NPs), nurses, physician assistants (PAs), pharmacists, researchers, fellows, and other healthcare professionals interested in the treatment of lung cancers may also participate.
At the conclusion of this symposium, you should be better prepared to:
Discuss evidence-based recommendations regarding tumor tissue testing and its role in therapeutic selection for the patients with NSCLC
Assess clinical decision-making necessary along multiple lines of care concerning the use of chemotherapeutic, targeted, and immunooncology strategies in the setting of NSCLC
Discuss evolving data sets on immunooncology strategies and their use in lung cancers
Describe the role of cytotoxic and antiangiogenic approaches in the management of advanced NSCLC
Explain optimized strategies to target oncogenic drivers in frontline settings and beyond disease progression
Describe advances and future directions for care in the management of squamous NSCLC, as well as treatment considerations for special populations of patients with lung cancer
Integrate personalized approaches to manage challenging cases and real-world clinical scenarios in advanced lung cancer settings
Thomas J. Lynch, Jr., MD
Chairman and Chief Executive Officer
Massachusetts General Physicians Organization
Heather A. Wakelee, MD
Associate Professor, Medicine (Oncology)
Stanford University Medical Center